Gross GJ - Search Results

1

Seven day oral supplementation with Cardax (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats.

Gross GJ, Hazen SL, Lockwood SF. Gross GJ, et al. Mol Cell Biochem. 2006 Feb;283(1-2):23-30. doi: 10.1007/s11010-006-2217-6. Mol Cell Biochem. 2006. PMID: 16444582

2

A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration.

Huang C, Liu Y, Beenken A, Jiang L, Gao X, Huang Z, Hsu A, Gross GJ, Wang YG, Mohammadi M, Schultz JEJ. Huang C, et al. Among authors: gross gj. Cardiovasc Res. 2017 Nov 1;113(13):1585-1602. doi: 10.1093/cvr/cvx165. Cardiovasc Res. 2017. PMID: 29016740 Free PMC article.

3

Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts.

Gross GJ, Hsu A, Falck JR, Nithipatikom K. Gross GJ, et al. J Mol Cell Cardiol. 2007 Mar;42(3):687-91. doi: 10.1016/j.yjmcc.2006.11.020. Epub 2007 Jan 10. J Mol Cell Cardiol. 2007. PMID: 17217955 Free PMC article.

4

Transient receptor potential vanilloid 1 inhibitors block laparotomy- and opioid-induced infarct size reduction in rats.

Heymann HM, Wu Y, Lu Y, Qvit N, Gross GJ, Gross ER. Heymann HM, et al. Among authors: gross gj. Br J Pharmacol. 2017 Dec;174(24):4826-4835. doi: 10.1111/bph.14064. Epub 2017 Nov 21. Br J Pharmacol. 2017. PMID: 28982207 Free PMC article.

5

Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning.

Gauthier KM, Yang W, Gross GJ, Campbell WB. Gauthier KM, et al. Among authors: gross gj. J Cardiovasc Pharmacol. 2007 Dec;50(6):601-8. doi: 10.1097/FJC.0b013e318159cbe3. J Cardiovasc Pharmacol. 2007. PMID: 18091575 Review.

6

Postischemic administration of CGX-1051, a peptide from cone snail venom, reduces infarct size in both rat and dog models of myocardial ischemia and reperfusion.

Lubbers NL, Campbell TJ, Polakowski JS, Bulaj G, Layer RT, Moore J, Gross GJ, Cox BF. Lubbers NL, et al. Among authors: gross gj. J Cardiovasc Pharmacol. 2005 Aug;46(2):141-6. doi: 10.1097/01.fjc.0000167015.84715.27. J Cardiovasc Pharmacol. 2005. PMID: 16044024

7

Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway.

Nithipatikom K, Gross ER, Endsley MP, Moore JM, Isbell MA, Falck JR, Campbell WB, Gross GJ. Nithipatikom K, et al. Among authors: gross er, gross gj. Circ Res. 2004 Oct 15;95(8):e65-71. doi: 10.1161/01.RES.0000146277.62128.6f. Epub 2004 Sep 23. Circ Res. 2004. PMID: 15388642

8

Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor.

Du L, Gao ZG, Nithipatikom K, Ijzerman AP, Veldhoven JP, Jacobson KA, Gross GJ, Auchampach JA. Du L, et al. Among authors: gross gj. J Pharmacol Exp Ther. 2012 Jan;340(1):210-7. doi: 10.1124/jpet.111.187559. Epub 2011 Oct 19. J Pharmacol Exp Ther. 2012. PMID: 22011434 Free PMC article.

9

Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism.

Ge ZD, Pravdic D, Bienengraeber M, Pratt PF Jr, Auchampach JA, Gross GJ, Kersten JR, Warltier DC. Ge ZD, et al. Among authors: gross gj. Anesthesiology. 2010 Jan;112(1):73-85. doi: 10.1097/ALN.0b013e3181c4a607. Anesthesiology. 2010. PMID: 19996950 Free PMC article.

10

Morphine enhances pharmacological preconditioning by isoflurane: role of mitochondrial K(ATP) channels and opioid receptors.

Ludwig LM, Patel HH, Gross GJ, Kersten JR, Pagel PS, Warltier DC. Ludwig LM, et al. Among authors: gross gj. Anesthesiology. 2003 Mar;98(3):705-11. doi: 10.1097/00000542-200303000-00019. Anesthesiology. 2003. PMID: 12606915

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results